VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+8.21%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$214M
AUM Growth
+$9.71M
(+4.8%)
Cap. Flow
+$1.5M
Cap. Flow
% of AUM
0.7%
Top 10 Holdings %
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36
Top Buys
| 1 |
OCCI
OFS Credit Co
OCCI
|
$2.06M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
$1.96M |
| 3 |
Applovin
APP
|
$1.49M |
| 4 |
Constellation Energy
CEG
|
$1.32M |
| 5 |
ECC
Eagle Point Credit Co
ECC
|
$1.26M |
Top Sells
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
$1.49M |
| 2 |
Gen Digital
GEN
|
$1.01M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$1M |
| 4 |
Adobe
ADBE
|
$989K |
| 5 |
Steris
STE
|
$907K |
Sector Composition
| 1 | Financials | 28.16% |
| 2 | Healthcare | 18.37% |
| 3 | Technology | 14.33% |
| 4 | Industrials | 8.16% |
| 5 | Consumer Discretionary | 6.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Nuvation Bio
NUVB
$1.33B
| $70.6K | 0.03% |
30,821
+545
| +2% | +$1.25K |
|
427
Liquidia Corp
LQDA
$2.48B
| $68.6K | 0.03% |
6,860
+119
| +2% | +$1.19K |
|
428
New Fortress Energy
NFE
$672M
| $68.6K | 0.03% |
7,543
+1,643
| +28% | +$14.9K |
|
429
Arcturus Therapeutics
ARCT
$485M
| $67.8K | 0.03% |
2,919
+54
| +2% | +$1.25K |
|
430
CureVac
CVAC
$1.21B
| $67.7K | 0.03% |
23,036
+405
| +2% | +$1.19K |
|
431
Arrowhead Research
ARWR
$4.02B
| $67.4K | 0.03% |
3,478
+62
| +2% | +$1.2K |
|
432
Vir Biotechnology
VIR
$732M
| $66.6K | 0.03% |
8,894
+156
| +2% | +$1.17K |
|
433
MacroGenics
MGNX
$126M
| $64.8K | 0.03% |
19,694
+351
| +2% | +$1.16K |
|
434
Stoke Therapeutics
STOK
$1.13B
| $64.6K | 0.03% |
5,256
+89
| +2% | +$1.09K |
|
435
Recursion Pharmaceuticals
RXRX
$2.01B
| $64.3K | 0.03% |
9,763
+173
| +2% | +$1.14K |
|
436
Larimar Therapeutics
LRMR
$337M
| $62.3K | 0.03% |
9,508
+166
| +2% | +$1.09K |
|
|
ITOS
437
DELISTED
iTeos Therapeutics
ITOS
| $57.7K | 0.03% |
5,655
+101
| +2% | +$1.03K |
|
438
Editas Medicine
EDIT
$248M
| $57.3K | 0.03% |
16,790
+301
| +2% | +$1.03K |
|
439
Sana Biotechnology
SANA
$752M
| $53.6K | 0.03% |
12,890
+229
| +2% | +$953 |
|
440
Precigen
PGEN
$1.3B
| $51.3K | 0.02% |
54,216
+966
| +2% | +$915 |
|
441
Lyell Immunopharma
LYEL
$233M
| $49.1K | 0.02% |
1,779
+31
| +2% | +$856 |
|
442
Prime Medicine
PRME
$663M
| $45.2K | 0.02% |
11,670
+211
| +2% | +$817 |
|
443
Taysha Gene Therapies
TSHA
$917M
| $44.4K | 0.02% |
22,103
+394
| +2% | +$792 |
|
444
Fulcrum Therapeutics
FULC
$414M
| $42.2K | 0.02% |
11,813
+207
| +2% | +$739 |
|
445
4D Molecular Therapeutics
FDMT
$340M
| $40.8K | 0.02% |
3,773
+64
| +2% | +$692 |
|
446
Zentalis Pharmaceuticals
ZNTL
$126M
| $35.6K | 0.02% |
9,683
+174
| +2% | +$640 |
|
447
Cabaletta Bio
CABA
$155M
| $34.6K | 0.02% |
7,338
+131
| +2% | +$618 |
|
|
AGEN
448
Agenus
AGEN
$138M
| $31.6K | 0.01% |
5,759
+101
| +2% | +$553 |
|
449
Kyverna Therapeutics
KYTX
$170M
| $31.2K | 0.01% |
6,381
+112
| +2% | +$548 |
|
450
ALX Oncology
ALXO
$57.8M
| $19.9K | 0.01% |
10,920
+194
| +2% | +$353 |
|